Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001104659-25-107349
Filing Date
2025-11-06
Accepted
2025-11-06 07:00:20
Documents
66
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 6-K prqr-20250930x6k.htm 6-K 24620
2 EX-99.1 prqr-20250930xex99d1.htm   iXBRL EX-99.1 765042
3 EX-99.2 prqr-20250930xex99d2.htm EX-99.2 392680
  Complete submission text file 0001104659-25-107349.txt   3663308

Data Files

Seq Description Document Type Size
4 EX-101.SCH prqr-20250930.xsd EX-101.SCH 48859
5 EX-101.CAL prqr-20250930_cal.xml EX-101.CAL 37407
6 EX-101.DEF prqr-20250930_def.xml EX-101.DEF 128692
7 EX-101.LAB prqr-20250930_lab.xml EX-101.LAB 271521
8 EX-101.PRE prqr-20250930_pre.xml EX-101.PRE 207854
69 EXTRACTED XBRL INSTANCE DOCUMENT prqr-20250930xex99d1_htm.xml XML 417253
Mailing Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK
Business Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK 31 88 166 7000
ProQR Therapeutics N.V. (Filer) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36622 | Film No.: 251456048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)